TNSN04100A1 - Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof , the use thereof as medicaments, in addition to a medicament containing same - Google Patents
Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof , the use thereof as medicaments, in addition to a medicament containing sameInfo
- Publication number
- TNSN04100A1 TNSN04100A1 TNP2004000100A TNSN04100A TNSN04100A1 TN SN04100 A1 TNSN04100 A1 TN SN04100A1 TN P2004000100 A TNP2004000100 A TN P2004000100A TN SN04100 A TNSN04100 A TN SN04100A TN SN04100 A1 TNSN04100 A1 TN SN04100A1
- Authority
- TN
- Tunisia
- Prior art keywords
- medicaments
- compounds
- treatment
- phenyltetrahydroisoquinolines
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
Abstract
THE INVENTION RELATES TO COMPOUNDS OF FORMULA (1); WHEREIN R1-R9 WHICH HAVE THE MEANING AS CITED IN THE CLAIMS; ARE EXTREMELY SUITABLE AS ANTIHYPERTENSIVES FOR REDUCING OR PREVENTING ISCHEMICALLY INDUCED INJURIES; AS MEDICAMENTS FOR OPERATIVE INTERVENTION FOR THE TREATMENT OF ISCHEMICS OF THE NERVOUS SYSTEM; STROKES AND SWELLING OF THE BRAIN; SHOCKS; DISTURBED RESPIRATORY FUNCTIONS; FOR THE TREATMENT OF SNORERS; AS A LAXATIVE; AS AGENTS AGAINST ECTOPIC PARASITES; FOR THE PREVENTION OF GALLSTONES; AS ANTIATHEROSCLEROTIC AGENTS; AGENTS AGAINST DIABETIC LATE COMPLICATIONS; CANCER; FIBROTIC DISEASES; ENDOTHELIAL DYSFUNCTIONS; ORGAN HYPERTROPHIA AND HYPERPLASIA SAID COMPOUNDS ARE ALSO INHIBITORS OF THE CELLULAR SODIUM – PROTON – ANTIPORTERS; THEY INFLUENCE SERUM LIPOPROTEIN AND CAN BE USED IN THE PROPHYLAXIS AND FOR THE REGRESSION OF ATHEROSCLEROTIC ALTERATIONS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10159714 | 2001-12-05 | ||
| PCT/EP2002/012990 WO2003048129A1 (en) | 2001-12-05 | 2002-11-20 | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN04100A1 true TNSN04100A1 (en) | 2006-06-01 |
Family
ID=7708117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2004000100A TNSN04100A1 (en) | 2001-12-05 | 2004-06-04 | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof , the use thereof as medicaments, in addition to a medicament containing same |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1453810B1 (en) |
| JP (1) | JP4510457B2 (en) |
| KR (1) | KR20050044724A (en) |
| CN (1) | CN100497314C (en) |
| AR (1) | AR037620A1 (en) |
| AT (1) | ATE425968T1 (en) |
| AU (1) | AU2002356689B2 (en) |
| BR (1) | BR0214753A (en) |
| CA (1) | CA2469385A1 (en) |
| CO (1) | CO5580748A2 (en) |
| DE (1) | DE50213372D1 (en) |
| DK (1) | DK1453810T3 (en) |
| EC (1) | ECSP045138A (en) |
| ES (1) | ES2324528T3 (en) |
| HK (1) | HK1072597A1 (en) |
| HR (1) | HRP20040507A2 (en) |
| HU (1) | HUP0600854A2 (en) |
| IL (1) | IL162316A0 (en) |
| MA (1) | MA27147A1 (en) |
| MX (1) | MXPA04005343A (en) |
| MY (1) | MY157371A (en) |
| NO (1) | NO326650B1 (en) |
| NZ (1) | NZ533322A (en) |
| OA (1) | OA12740A (en) |
| PE (1) | PE20030726A1 (en) |
| PL (1) | PL369313A1 (en) |
| PT (1) | PT1453810E (en) |
| RS (1) | RS48004A (en) |
| RU (1) | RU2298003C2 (en) |
| TN (1) | TNSN04100A1 (en) |
| TW (1) | TWI281860B (en) |
| UA (1) | UA77042C2 (en) |
| WO (1) | WO2003048129A1 (en) |
| ZA (1) | ZA200403711B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312963A1 (en) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| DE102004046492A1 (en) * | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them |
| US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| DE102005001411A1 (en) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them |
| EP1853586B1 (en) | 2005-02-18 | 2013-07-24 | AstraZeneca AB | Antibacterial piperidine derivatives |
| CN101171247A (en) * | 2005-03-04 | 2008-04-30 | 阿斯利康(瑞典)有限公司 | Pyrrole derivatives as DNA gyrase and topoisomerase inhibitors |
| DE102005044817A1 (en) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them |
| DE102006012545A1 (en) | 2006-03-18 | 2007-09-27 | Sanofi-Aventis | Substituted 2-amino-4-phenyl-dihydroquinolines, process for their preparation, their use as medicament, and medicament containing them |
| CN103819403B (en) * | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | For treating the disease relevant with fluid retention or salt over loading and the Compounds and methods for of disorder of gastrointestinal tract |
| WO2018129556A1 (en) * | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| KR102138391B1 (en) * | 2012-08-21 | 2020-07-27 | 알데릭스, 인코포레이티드 | Compounds and methods for inhibiting nhe-mediaded antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| KR20230132619A (en) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| CN103788084A (en) * | 2014-03-02 | 2014-05-14 | 湖南华腾制药有限公司 | Tetrahydroisoquinoline derivative and synthesis method thereof |
| SG11201700398RA (en) * | 2014-07-25 | 2017-02-27 | Taisho Pharmaceutical Co Ltd | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl |
| JP6903923B2 (en) * | 2016-01-22 | 2021-07-14 | 大正製薬株式会社 | A drug containing a phenyltetrahydroisoquinoline compound substituted with a heteroaryl as an active ingredient. |
| EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
| AU2018205400B2 (en) * | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| EP4265608A1 (en) * | 2020-12-18 | 2023-10-25 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Benzoheterocycle substituted tetrahydroisoquinoline compound |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19951702A1 (en) * | 1999-10-27 | 2001-05-03 | Aventis Pharma Gmbh | Use of 2-amino-3,4-dihydroquinazolines for the manufacture of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions |
| RU2309953C2 (en) * | 1999-11-03 | 2007-11-10 | Эймр Текнолоджи, Инк. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines, pharmaceutical composition and method for treatment based on thereof |
| CN100436420C (en) * | 1999-11-03 | 2008-11-26 | Amr科技公司 | 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| DE10019062A1 (en) * | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia |
-
2002
- 2002-11-20 PT PT02804183T patent/PT1453810E/en unknown
- 2002-11-20 BR BR0214753-0A patent/BR0214753A/en not_active IP Right Cessation
- 2002-11-20 HU HU0600854A patent/HUP0600854A2/en unknown
- 2002-11-20 KR KR1020047008697A patent/KR20050044724A/en active IP Right Grant
- 2002-11-20 MX MXPA04005343A patent/MXPA04005343A/en active IP Right Grant
- 2002-11-20 WO PCT/EP2002/012990 patent/WO2003048129A1/en active Application Filing
- 2002-11-20 IL IL16231602A patent/IL162316A0/en unknown
- 2002-11-20 CA CA002469385A patent/CA2469385A1/en not_active Abandoned
- 2002-11-20 ES ES02804183T patent/ES2324528T3/en not_active Expired - Lifetime
- 2002-11-20 DE DE50213372T patent/DE50213372D1/en not_active Expired - Lifetime
- 2002-11-20 NZ NZ533322A patent/NZ533322A/en unknown
- 2002-11-20 AU AU2002356689A patent/AU2002356689B2/en not_active Ceased
- 2002-11-20 JP JP2003549321A patent/JP4510457B2/en not_active Expired - Fee Related
- 2002-11-20 RS YU48004A patent/RS48004A/en unknown
- 2002-11-20 PL PL02369313A patent/PL369313A1/en not_active Application Discontinuation
- 2002-11-20 RU RU2004120295/04A patent/RU2298003C2/en not_active IP Right Cessation
- 2002-11-20 DK DK02804183T patent/DK1453810T3/en active
- 2002-11-20 EP EP02804183A patent/EP1453810B1/en not_active Expired - Lifetime
- 2002-11-20 AT AT02804183T patent/ATE425968T1/en not_active IP Right Cessation
- 2002-11-20 CN CNB028278879A patent/CN100497314C/en not_active Expired - Fee Related
- 2002-11-20 OA OA1200400166A patent/OA12740A/en unknown
- 2002-11-20 UA UA20040705310A patent/UA77042C2/en unknown
- 2002-11-26 PE PE2002001138A patent/PE20030726A1/en not_active Application Discontinuation
- 2002-12-03 AR ARP020104667A patent/AR037620A1/en unknown
- 2002-12-03 TW TW091134977A patent/TWI281860B/en not_active IP Right Cessation
- 2002-12-04 MY MYPI20024565A patent/MY157371A/en unknown
-
2004
- 2004-05-14 ZA ZA200403711A patent/ZA200403711B/en unknown
- 2004-05-21 MA MA27693A patent/MA27147A1/en unknown
- 2004-05-25 NO NO20042158A patent/NO326650B1/en not_active IP Right Cessation
- 2004-06-03 CO CO04052088A patent/CO5580748A2/en not_active Application Discontinuation
- 2004-06-04 TN TNP2004000100A patent/TNSN04100A1/en unknown
- 2004-06-04 EC EC2004005138A patent/ECSP045138A/en unknown
- 2004-06-04 HR HR20040507A patent/HRP20040507A2/en not_active Application Discontinuation
-
2005
- 2005-06-22 HK HK05105174.2A patent/HK1072597A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN04100A1 (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof , the use thereof as medicaments, in addition to a medicament containing same | |
| BRPI0307351B8 (en) | compound, pharmaceutical composition, use of a compound, and, process for preparing a compound | |
| BR0213233A (en) | Matrix metalloproteinase inhibitor alkynes | |
| UA83182C2 (en) | Compounds effecting glucokinase | |
| GB0225475D0 (en) | Therapeutic agents | |
| GB0318447D0 (en) | Therapeutic agents | |
| BR0212042A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound | |
| MXPA04012965A (en) | Viral inhibitors. | |
| DE60234577D1 (en) | PHARMACEUTICAL MIXTURE FOR THE TREATMENT OF CANCER CONTAINING DIOXOLANE NUCLEOSIDE ANALOGUE | |
| CY1109191T1 (en) | A NEW USE OF DIFFERIPRON | |
| ATE190840T1 (en) | COMPOSITION FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| BR0207316A (en) | Epothilone derivatives for the treatment of refractory tumors | |
| BR0316458A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound | |
| WO2001092218A3 (en) | Polyamine analogues as therapeutic and diagnostic agents | |
| SE9902267D0 (en) | New compounds | |
| NO20022801L (en) | Substituted norbornylamino derivatives, processes for their preparation, their use as a medicament or diagnostic as well as drugs containing these | |
| BR0312470A (en) | Compound, use thereof, pharmaceutical composition, method of treating and / or preventing cancer, and process for preparing the compound | |
| AU2002361028A1 (en) | Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same | |
| WO2003053352A3 (en) | Therapeutic compounds for treating dyslipidemic conditions | |
| BR0112609A (en) | Aniline Derivatives | |
| DK0985414T3 (en) | Drug for the treatment of glaucoma and ischemic retinopathy | |
| PT1196170E (en) | Use of a macrolide compound for the preparation of a medicament for the treatment of ischemic or hemorrhagic cranial lesions | |
| DE60022047D1 (en) | ANTIVIRAL THERAPY | |
| ATE270886T1 (en) | ANTIVIRAL THERAPY | |
| MX9603819A (en) | Treatment of tinntus using neuroprotective agents. |